Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04647032
Other study ID # 132026a
Secondary ID R21AG062395
Status Completed
Phase N/A
First received
Last updated
Start date January 11, 2021
Est. completion date May 31, 2022

Study information

Verified date April 2023
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall goal of this project is to improve cognitive control abilities in adults with mild cognitive impairment (MCI) through a form of non-invasive brain stimulation, transcranial alternating current stimulation (tACS).


Description:

30 older adults aged 60-80 years with md-aMCI were randomized to 8 sessions of transcranial alternating current stimulation (tACS) with simultaneous cognitive control training (CCT). The intervention took place within the participant's home without direct researcher assistance. Half of the participants received prefrontal theta tACS during CCT and the other half received control tACS. Outcomes were assessed pre and post intervention.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria: - English speaking - Grade 12 or more education - Normal or corrected to normal vision and hearing - Ability to complete cognitive tasks - Ability to cooperate and comply with all study procedures - Ability to tolerate tACS - Montreal Cognitive Assessment score: 17-28 - -1 z-score on immediate memory, delayed memory, fluency, processing speed, or task switch - Self-reported memory complaint Exclusion Criteria: - Neurological or psychiatric disorders other than mild cognitive impairment - Receiving investigational medications or have participated in a trial with investigational medications within last 30 days - Family history of epilepsy - Implanted electronic devices (e.g., pacemaker) - Prior head trauma - Pregnant - IQ < 80 - Taking cholinesterase inhibitory, memantine, or psychotropic medication - Taking anti-depressants or anti-anxiety medication - Color blind - Substance abuse - Glaucoma - Macular degeneration - Amblyopia (lazy eye) - Strabismus (crossed eyes)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcranial alternating current stimulation
Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4

Locations

Country Name City State
United States University of California, San Francisco San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Divided Attention Performance Divided attention was assessed as the difficulty level achieved during perceptual discrimination performance while participants were engaged in the Akili AKL-T01 task. Higher is better. Post-tACS (1-day follow-up), approximately 1 week after baseline
Primary Divided Attention Performance Divided attention was assessed as the difficulty level achieved during perceptual discrimination performance while participants were engaged in the Akili AKL-T01 task. Higher is better. Post-tACS (1-month follow-up), approximately 1 month after baseline
Primary Sustained Attention Performance Sustained attention was assessed via response times to visual targets during the continuous performance task. Lower is better. Post-tACS (1-day follow-up), approximately 1 week after baseline
Primary Sustained Attention Performance Sustained attention was assessed via response times to visual targets during the continuous performance task. Lower is better. Post-tACS (1-month follow-up), approximately 1 month after baseline
Primary Working Memory Performance Working memory was assessed as the average maximum number correct from the ACE-X span tasks - memory for order of illuminated squares. Post-tACS (1-day follow-up), approximately 1 week after baseline
Primary Working Memory Performance Working memory was assessed as the average maximum number correct from the ACE-X span tasks - memory for order of illuminated squares Post-tACS (1-month follow-up), approximately 1 month after baseline
Secondary Instrumental Activities of Daily Living (IADL) Scores on the IADL will be assessed pre and post intervention. Higher scores are better (minimum = 0, maximum = 4). Post-tACS (1-day follow-up), approximately 1 week after baseline
Secondary Instrumental Activities of Daily Living (IADL) Scores on the IADL will be assessed pre and post intervention. Higher scores are better (minimum = 0, maximum = 4). Post-tACS (1-month follow-up), approximately 1 month after baseline
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A